ES2090858T3 - Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas. - Google Patents

Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas.

Info

Publication number
ES2090858T3
ES2090858T3 ES93301861T ES93301861T ES2090858T3 ES 2090858 T3 ES2090858 T3 ES 2090858T3 ES 93301861 T ES93301861 T ES 93301861T ES 93301861 T ES93301861 T ES 93301861T ES 2090858 T3 ES2090858 T3 ES 2090858T3
Authority
ES
Spain
Prior art keywords
glutation
stimulator
source
treatment
omega
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93301861T
Other languages
English (en)
Inventor
David A Mark
W Bruce Rowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transcend Therapeutics Inc
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Application granted granted Critical
Publication of ES2090858T3 publication Critical patent/ES2090858T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL PRESENTE INVENTO PREVE UN METODO PARA TRATAR UNA INFECCION VIRAL O DESORDEN INMUNOLOGICO, ASI COMO LAS COMPOSICIONES DEL MISMO. EL METODO DE TRATAMIENTO COMPRENDE LA ADMINISTRACION A UN PACIENTE QUE TIENE UNA INFECCION VIRAL O UN DESORDEN INMUNOLOGICO, UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UNA COMPOSICION QUE INCLUYE UN ESTIMULADOR GLUTATIONE INTRACELULAR Y UNA FUENTE DE ACIDO GRASO OMEGA - 3.
ES93301861T 1992-04-08 1993-03-11 Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas. Expired - Lifetime ES2090858T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/865,288 US5214062A (en) 1992-04-08 1992-04-08 Method and composition for treating immune disorders, inflammation and chronic infections

Publications (1)

Publication Number Publication Date
ES2090858T3 true ES2090858T3 (es) 1996-10-16

Family

ID=25345142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93301861T Expired - Lifetime ES2090858T3 (es) 1992-04-08 1993-03-11 Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas.

Country Status (7)

Country Link
US (1) US5214062A (es)
EP (1) EP0567216B1 (es)
JP (1) JPH0625006A (es)
AU (1) AU663923B2 (es)
CA (1) CA2093163A1 (es)
DE (1) DE69304118T2 (es)
ES (1) ES2090858T3 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
ES2092539T3 (es) * 1991-01-10 1996-12-01 Transcend Therapeutics Inc Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
EP0535390B1 (en) * 1991-09-30 1996-05-15 Transcend Therapeutics, Inc. The use of L-2-oxothiazolidine-4-carboxylate for the preparation of a medicament for treating latent HIV infection
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
AU5040493A (en) * 1992-11-30 1994-06-09 Transcend Therapeutics, Inc Method for treating systemic inflammatory response syndrome
FR2711529B1 (fr) † 1993-10-28 1996-07-05 Clintec Nutrition Cy Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5397778A (en) * 1994-02-25 1995-03-14 New England Deaconess Hospital Corporation Enteral formulations for treatment of inflammation and infection
JPH10500937A (ja) * 1994-02-25 1998-01-27 ニュー イングランド ディーコネス ホスピタル コーポレイション セサミン系リグナンの抗炎症及び感染防護効果
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE19629433A1 (de) * 1996-07-22 1998-01-29 Hoechst Ag Omega-3-fettsäurenenthaltende Zubereitung aus Mikroorganismen als Prophylaktikum bzw. Therapeutikum gegen parasitäre Erkrankungen beim Tier
DE19652586A1 (de) * 1996-12-17 1998-06-18 Biotechnolog Forschung Gmbh Dhc-Peptid und Mittel
JP4578578B2 (ja) * 1997-01-13 2010-11-10 エモリー、ユニバーシティ インフルエンザ感染の治療用化合物及びそれらの組み合わせ
US6055936A (en) * 1997-01-21 2000-05-02 Collin; Peter Donald Sea cucumber carotenoid lipid fractions and process
US5776463A (en) * 1997-02-19 1998-07-07 Arginteanu; Ronit Method of reducing stress and circulatory heart disease with freeze-dried borage petal extracts
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
US6197749B1 (en) * 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
CN1195544C (zh) * 1998-07-30 2005-04-06 森永乳业株式会社 用于慢性肝炎的肝功能改善剂
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US7012086B1 (en) 2000-06-30 2006-03-14 The Foundation For Innovative Therapies, Inc. Treatment of retrovirus induced derangements with niacin compounds
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (en) * 2001-03-23 2005-05-11 Luitpold Pharm Inc FAT AMIN DRUG CONJUGATES
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
WO2006069293A2 (en) * 2004-12-22 2006-06-29 Friedman Robert S Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
WO2007030492A2 (en) * 2005-09-06 2007-03-15 Guilford F Timothy Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione
WO2007044700A2 (en) * 2005-10-07 2007-04-19 Board Of Trustees Of Southern Illinois University Protectant combinations for reducing toxicities
US20070149617A1 (en) * 2005-11-14 2007-06-28 Deckelbaum Richard J Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
US11039997B2 (en) 2005-12-27 2021-06-22 Ruth-Maria Korth Cosmetic, dermatic, protective compositions comprising phospholipids, lecithins with peptides and at least one acetylating compound
DE102005062417A1 (de) * 2005-12-27 2007-08-23 Korth, Ruth-Maria, Dr.med. Kompositionen mit spezifischen und unspezifischen Lipidantagonisten
CN100434062C (zh) * 2006-08-28 2008-11-19 卢小明 L-2-氧代硫氮杂戍环烷-4-羧酸及其酯类衍生物作为皮肤药妆品的应用
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
HK1221119A1 (zh) 2013-03-28 2017-05-26 The Trustees Of Columbia University In The City Of New York 用omega-3甘油酯再灌注促进对用於移植的供体器官的保护

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476624A (en) * 1973-05-30 1977-06-16 Cepbepe Tranquiliser medicaments
EP0087865B1 (en) * 1982-03-01 1986-10-01 Efamol Limited Pharmaceutical composition
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
HU200177B (en) * 1985-06-18 1990-04-28 Biogal Gyogyszergyar Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds
US5053387A (en) * 1987-02-20 1991-10-01 Shriners Hospitals For Crippled Children Omega-3 fatty acids in traumatic injury treatment
GB8918294D0 (en) * 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
DE69124223T2 (de) * 1990-02-05 1997-04-30 Lifescience Corp Vitamine und mineralien enthaltende nahrungszusätze
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
DE69220821T2 (de) * 1991-02-04 1997-11-20 Nestle Sa Verfahren zur Sicherstellung eines angemessenen intrazellulären Glutathionspiegels im Gewebe
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments

Also Published As

Publication number Publication date
AU663923B2 (en) 1995-10-26
DE69304118D1 (de) 1996-09-26
DE69304118T2 (de) 1997-03-06
JPH0625006A (ja) 1994-02-01
US5214062A (en) 1993-05-25
EP0567216A1 (en) 1993-10-27
AU3409293A (en) 1993-10-14
CA2093163A1 (en) 1993-10-09
EP0567216B1 (en) 1996-08-21

Similar Documents

Publication Publication Date Title
ES2090858T3 (es) Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas.
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
ES2053990T3 (es) Composiciones de acidos grasos esenciales.
BR9307104A (pt) Preparações reforçadora de mecanismos de defesa de hospedeiros e migrante com pico único b-glicano hidrossolúvel métodos para produzir uma preparação reforçadora de meanismos de defesa de hospedeiros para impedir infecção em um mamífero para estimular o reparo e cura de uma ferida e para estimular a proliferação de plaquetas composição farmacêutica e método para tratar infecção em mamíferos
SE8504967D0 (sv) A pharmaceutical composition and a method of treating the body
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
ES2058799T3 (es) Composiciones estabilizadas que contienen factor de crecimiento epidermico.
MX9302160A (es) Composiciones farmaceuticas del interferon de leu cocito humano concordante.
ES2106794T3 (es) Utilizacion del inositol-trifosfato para el tratamiento de inflamaciones.
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
ES2174921T3 (es) Inhibidores de la proteasa del vih.
WO2022010813A3 (en) Enhancing immune responses through targeted antigen expression
WO2022159501A3 (en) Methods and compositions for treating neurodegenerative diseases
BG100599A (en) Antiviral form and therapeutical method
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
ES2078251T3 (es) Sistema para la distribucion regulada de agentes activos y proceso para su preparacion.
MX9304925A (es) Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer.
CA2150234C (en) COMBINATION OF ATOVAQUONE AND PROGUANIL FOR THE TREATMENT OF PROTOZOA INFECTION
SE8403659L (sv) Synergistiska farmaceutiska kompositioner
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
CR20220453A (es) Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen
ES2148268T3 (es) Composicion farmaceutica para prevenir o tratar fracturas de huesos.
EP1374873A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR SUPPRESSING THE SIDE EFFECTS OF RADIATION THERAPY AND CHEMOTHERAPY

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567216

Country of ref document: ES

FG2A Definitive protection

Ref document number: 567216

Country of ref document: ES